Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HD003 cell therapy in relapsed or refractory multiple myeloma
CTR20234329Phase 2Active
- Sponsor
- Huadao Biomedical
- Start
- Jan 2024
- Countries
- 1
01
Overview
A Phase 2 trial of HD003 in multiple myeloma (MM), sponsored by Huadao Biomedical. Started Jan 2024; status: active.
02
Drugs
HD003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20234329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234329.